KZR Straddle Strategy

KZR (Kezar Life Sciences, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.

KZR (Kezar Life Sciences, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $53.9M, a beta of 0.41 versus the broader market, a 52-week range of 3.53-7.55, average daily share volume of 88K, a public-listing history dating back to 2018, approximately 55 full-time employees. These structural characteristics shape how KZR stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.41 indicates KZR has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a straddle on KZR?

A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.

Current KZR snapshot

As of May 13, 2026, spot at $23.61, ATM IV 251.90%, IV rank 49.69%, expected move 72.22%. The straddle on KZR below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 36-day expiry.

Why this straddle structure on KZR specifically: KZR IV at 251.90% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 72.22% (roughly $17.05 on the underlying). The 36-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated KZR expiries trade a higher absolute premium for lower per-day decay. Position sizing on KZR should anchor to the underlying notional of $23.61 per share and to the trader's directional view on KZR stock.

KZR straddle setup

The KZR straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With KZR near $23.61, the first option leg uses a $23.61 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed KZR chain at a 36-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 KZR shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$23.61	N/A
Buy 1	Put	$23.61	N/A

KZR straddle risk and reward

Net Premium / Debit: N/A
Max Profit (per contract): Unbounded
Max Loss (per contract): Unbounded
Breakeven(s): None on modeled curve
Risk / Reward Ratio: N/A

Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.

KZR straddle payoff curve

Modeled P&L at expiration across a range of underlying prices for the straddle on KZR. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use straddle on KZR

Straddles on KZR are pure-volatility plays that profit from large moves in either direction; traders typically buy KZR straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.

KZR thesis for this straddle

The market-implied 1-standard-deviation range for KZR extends from approximately $6.56 on the downside to $40.66 on the upside. A KZR long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current KZR IV rank near 49.69% is mid-range against its 1-year distribution, so the IV signal is neutral; the straddle thesis on KZR should anchor more to the directional view and the expected-move geometry. As a Healthcare name, KZR options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to KZR-specific events.

KZR straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. KZR positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move KZR alongside the broader basket even when KZR-specific fundamentals are unchanged. Always rebuild the position from current KZR chain quotes before placing a trade.

Frequently asked questions

What is a straddle on KZR?: A straddle on KZR is the straddle strategy applied to KZR (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With KZR stock trading near $23.61, the strikes shown on this page are snapped to the nearest listed KZR chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are KZR straddle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the KZR straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 251.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a KZR straddle?: The breakeven for the KZR straddle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current KZR market-implied 1-standard-deviation expected move is approximately 72.22%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a straddle on KZR?: Straddles on KZR are pure-volatility plays that profit from large moves in either direction; traders typically buy KZR straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
How does current KZR implied volatility affect this straddle?: KZR ATM IV is at 251.90% with IV rank near 49.69%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.